Green Cross, TaKaRa Bio to develop new cancer immunotherapy
Published: 2007-09-12 06:58:00
Updated: 2007-09-12 06:58:00
Korea Green Cross Corporation has signed an agreement with TaKaRa Bio Inc., an innovative biotechnology company based in Shiga, Japan, for the joint development and commercialization of new immunotherapy using TaKaRa Bio's RetroNectin technology.
RetroNectin, TaKaRa Bio's proprietary recombina...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
